ASH recap: New regimens for blood cancers; gene therapy equitable for sickle cell disease

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.
Abstracts highlighted notable advances in follicular lymphoma, acute lymphoblastic leukemia and mantle cell lymphoma, among other malignancies.
Other studies examined whether gene therapy would be an equitable therapeutic strategy for sickle cell disease and identified factors that may predict thromboembolism risk among individuals with cancer and COVID-19.
Healio presents the following 12 updates from ASH that may be relevant to your practice.
1. Zanubrutinib (Brukinsa,

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.
Abstracts highlighted notable advances in follicular lymphoma, acute lymphoblastic leukemia and mantle cell lymphoma, among other malignancies.
Other studies examined whether gene therapy would be an equitable therapeutic strategy for sickle cell disease and identified factors that may predict thromboembolism risk among individuals with cancer and COVID-19.
Healio presents the following 12 updates from ASH that may be relevant to your practice.
1. Zanubrutinib (Brukinsa,